Reuters -- Germany’s Merck KGaA met with U.S. regulators in January about the approval process for its multiple sclerosis pill cladribine but does not yet have a clear timetable for resubmitting the drug.
Reuters -- Germany’s Merck KGaA met with U.S. regulators in January about the approval process for its multiple sclerosis pill cladribine but does not yet have a clear timetable for resubmitting the drug.
